J Korean Med Sci.  2013 Dec;28(12):1703-1710. 10.3346/jkms.2013.28.12.1703.

Comparison of the Safety of Seven Iodinated Contrast Media

• Seong JM
• Choi NK
• Lee J
• Chang Y
• Kim YJ
• Yang BR
• Jin XM
• Kim JY
• Park BJ

• KMID: 1779408
• DOI: http://doi.org/10.3346/jkms.2013.28.12.1703

Abstract

We aimed to determine the characteristic adverse events (AEs) of iodinated contrast media (IOCM) and to compare the safety profiles of different IOCM. This study used the database of AEs reports submitted by healthcare professionals from 15 Regional Pharmacovigilance Centers between June 24, 2009 and December 31, 2010 in Korea. All reports of IOCM, including iopromide, iohexol, iopamidol, iomeprol, ioversol, iobitridol and iodixanol, were analyzed. Safety profiles were compared between different IOCM at the system organ level using the proportional reporting ratio (PRR) and 95% confidence interval (95% CI). Among a total of 48,261 reports, 6,524 (13.5%) reports were related to the use of IOCM. Iopromide (45.5%), iohexol (16.9%), iopamidol (14.3%) and iomeprol (10.3%) were identified as frequently reported media. 'Platelet, bleeding & clotting disorders' (PRR, 29.6; 95%CI, 1.9-472.6) and 'urinary system disorders' (PRR, 22.3; 95% CI, 17.1-29.1) were more frequently reported for iodixanol than the other IOCM. In conclusion, the frequency of AEs by organ class was significantly different between individual media. These differences among different IOCM should be considered when selecting a medium among various IOCM and when monitoring patients during and after its use to ensure optimum usage and patient safety.

Keyword

Contrast Media; Adverse Drug Reaction Reporting Systems; Patient Safety

MeSH Terms

Adolescent
Adult
Aged
Aged, 80 and over
Blood Platelet Disorders/chemically induced
Child
Child, Preschool
Contrast Media/*adverse effects/diagnostic use
Databases, Factual
Female
Humans
Infant
Infant, Newborn
Iodine Radioisotopes/chemistry
Male
Middle Aged
Neoplasms/radionuclide imaging
Radiopharmaceuticals/*adverse effects/diagnostic use
Urologic Diseases/chemically induced
Young Adult
Contrast Media
Iodine Radioisotopes
Radiopharmaceuticals

Reference

1. Kalra MK, Maher MM, D'Souza R, Saini S. Multidetector computed tomography technology: current status and emerging developments. J Comput Assist Tomogr. 2004; 28:S2–S6.

2. Katzberg RW, Haller C. Contrast-induced nephrotoxicity: clinical landscape. Kidney Int Suppl. 2006; 100:S3–S7.

3. Cochran ST, Bomyea K, Sayre JW. Trends in adverse events after IV administration of contrast media. AJR Am J Roentgenol. 2001; 176:1385–1388.

4. Wang CL, Cohan RH, Ellis JH, Caoili EM, Wang G, Francis IR. Frequency, outcome, and appropriateness of treatment of nonionic iodinated contrast media reactions. AJR Am J Roentgenol. 2008; 191:409–415.

5. Shin MJ, Cho YJ. Management of adverse reaction to iodinated radiocontrast media. J Korean Med Assoc. 2012; 55:779–790.

6. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003; 348:491–499.

7. Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, Gelormini JL, Labinaz M, Moreyra AE. Investigators of the CARE Study. Cardiac Angiography in Renally Impaired Patients (CARE) Study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007; 115:3189–3196.

8. Laskey W, Aspelin P, Davidson C, Rudnick M, Aubry P, Kumar S, Gietzen F, Wiemer M. DXV405 Study Group. Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures. Am Heart J. 2009; 158:822–828.

9. Rossi AC, Knapp DE, Anello C, O'Neill RT, Graham CF, Mendelis PS, Stanley GR. Discovery of adverse drug reactions: a comparison of selected phase IV studies with spontaneous reporting methods. JAMA. 1983; 249:2226–2228.

10. Choi NK, Park BJ. Adverse drug reaction surveillance system in Korea. J Prev Med Public Health. 2007; 40:278–284.

11. Shin YS, Lee YW, Choi YH, Park B, Jee YK, Choi SK, Kim EG, Park JW, Hong CS. Spontaneous reporting of adverse drug events by Korean regional pharmacovigilance centers. Pharmacoepidemiol Drug Saf. 2009; 18:910–915.

12. Uppsala Monitoring Centre. The WHO adverse reaction terminology (WHO-ART): terminology for coding clinical information in relation to drug therapy. accessed on 5 March 2013. Available at http://www.umc-products.com/graphics/3149.pdf.

13. International Conference on Harmonization. E2D: post-approval safety data management: definitions and standards for expedited reporting. accessed on 5 March 2013. Available at http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf.

14. Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009; 18:427–436.

15. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001; 10:483–486.

16. Van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002; 11:3–10.

17. Waller P, Heeley E, Moseley J. Impact analysis of signals detected from spontaneous adverse drug reaction reporting data. Drug Saf. 2005; 28:843–850.

18. Korea Institute of Drug Safety & Risk Management. Algorithm for signal detection and safety information generation. 2012.

19. Thomsen HS. Recent hot topics in contrast media. Eur Radiol. 2011; 21:492–495.

20. IMS Health Korea. Korea Market Survey of contrast medium, 2009 1Q. 2009.

21. Meth MJ, Maibach HI. Current understanding of contrast media reactions and implications for clinical management. Drug Saf. 2006; 29:133–141.

22. Gomi T, Nagamoto M, Hasegawa M, Katoh A, Sugiyama M, Murata N, Kunihiro T, Kohda E. Are there any differences in acute adverse reactions among five low-osmolar non-ionic iodinated contrast media? Eur Radiol. 2010; 20:1631–1635.

23. Thomsen HS, Morcos SK. Contrast-medium-induced nephropathy: is there a new consensus? a review of published guidelines. Eur Radiol. 2006; 16:1835–1840.

24. Heinrich MC, Häberle L, Müller V, Bautz W, Uder M. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology. 2009; 250:68–86.

25. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002; 39:930–936.

26. American College of Radiology. ACR manual on contrast media: version 7. 2010.

27. Van Grootheest K, de Graaf L, de Jong-van den Berg LT. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf. 2003; 26:211–217.

28. Figueras A, Capellà D, Castel JM, Laorte JR. Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs: a report from the Spanish System of Pharmacovigilance, including an early analysis of topical and enteric-coated formulations. Eur J Clin Pharmacol. 1994; 47:297–303.

29. Routledge PA, Lindquist M, Edwards IR. Spontaneous reporting of suspected adverse reactions to antihistamines: a national and international perspective. Clin Exp Allergy. 1999; 29:240–246.

30. Pierfitte C, Bégaud B, Lagnaoui R, Moore ND. Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol. 1999; 47:329–331.